Neuroepidemiology of amyotrophic lateral sclerosis: Clues to aetiology and pathogenesis

Journal of Neurology Neurosurgery and Psychiatry

Volumn 61, Issue 2, 1996, Pages 131-137

  Román, Gustavo C ^a,b  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; EPIDEMIOLOGY; HUMAN; INCIDENCE; MOTONEURON; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0029788989     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.61.2.131     Document Type: Short Survey

References (87)

1. Charcot JM. Lectures on the diseases of the nervous system. Translated and edited by Sigerson G. Three volumes, second series. London: The New Sydenham Society, 1881.
2. World Federation of Neurology Research Group on Neuromuscular Disorders. Classification of neuromuscular disorders. J Neurol Sci 1994;124(suppl):109-30.
3. World Federation of Neurology Research Group on Neuromuscular Disorders. El Escorial World Federation of Neurology Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis. J Neurol Sci 1994;124(suppl):96-107.
4. Ray Chaudhuri K, Crump S, al-Sarraj S, Anderson V, Cavanagh J, Leigh PN. The validation of El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis: a clinicopathological study. J Neurol Sci 1995;129 (suppl):11-2.
5. World Health Organisation. Neurological adaptation of the 10th International Classification of Diseases (ICD-10 NA), Geneva: WHO, 1994.
6. Armon C. Motor neuron disease. In: Gorelick PB, Alter M, eds. Handbook of neuroepidemiology. New York: Dekker, 1994:407-54.
7. Chancellor AM, Warlow CP. Adult onset motor neuron disease: worldwide mortality, incidence, and distribution since 1950. J Neurol Neurosurg Psychiatry 1992;55: 1106-15.
8. Rosati G, Granieri E. Manuale di Neuroepidemiologia Clinica. Roma: NIS, 1990:295-317.
9. De Pedro-Cuesta J, Litvan I. Epidemiology of motor neuron disease. In: Anderson DW, ed. Neuroepidemiology: a tribute to Bruce Schoenberg. Boca Raton: CRC Press, 1991:265-96.
10. Hoffman PM, Brody JA. The reliability of death certificate reporting for amyotrophic lateral sclerosis. Journal of Chronic Diseases 1971;24:5-8.
11. O'Malley F, Dean G, Elian M. Multiple sclerosis and motor neurone disease: survival and how certified after death. J Epidemiol Community Health 1987;41:14-7.
12. Chiò A, Magnani C, Oddenino E, Tolardo G, Schiffer D. Accuracy of death certificate diagnosis of amyotrophic lateral sclerosis. J Epidemiol Community Health 1992;46: 517-8.
13. Chancellor AM, Swingler RJ, Fraser H, Clarke JA, Warlow CP. Utility of Scottish morbidity and mortality data for epidemiological studies of motor neuron disease. J Epidemiol Community Health 1993;47:116-20.
14. Neilson S, Gunnarsson L-G, Robinson I. Rising mortality from motor neuron disease in Sweden 1961-1990: the relative role of increased population life expectancy and environmental factors. Acta Neurol Scand 1994;90:150-9.
15. Elian M, Dean G. The changing mortality from motor neuron disease and multiple sclerosis in England and Wales and the Republic of Ireland. Neuroepidemiology 1991; 11:236-43.
16. Leone M, Chandra V, Schoenberg BS. Motor neuron disease in the United States, 1971 and 1973-1978. Neurology 1987;37:1339-43.
17. Neilson S, Robinson I, Hunter M. Longitudinal Gompertzian analysis of ALS mortality in England and Wales, 1963-1989: estimates of susceptibility in the general population. Mech Ageing Dev 1992;64:201-16.
18. Jokelainen M. The epidemiology of amyotrophic lateral sclerosis in Finland. J Neurol Sci 1976;29:55-63.
19. Neilson S, Robinson I, Alperovitch A. Rising amyotrophic lateral sclerosis mortality in France, 1968-1990: increased life expectancy and inter-disease competition as an explanation. J Neurol 1994;241:448-55.
20. Chiò A, Magnani C, Schiffer D. Amyotrophic lateral sclerosis in Italy, 1958 to 1987: a cross-sectional and cohort study. Neurology 1993;43:927-30.
21. Neilson S, Robinson I, Nymoen EH. Longitudinal analysis of amyotrophic lateral sclerosis mortality in Norway, 1966-1989: evidence for a susceptible subpopulation. J Neurol Sci 1994;122:148-54.
22. Neilson S, Robinson I, Kondo K. A new analysis of mortality from motor neuron disease in Japan, 1950-1990: rise and fall in the postwar years. J Neurol Sci 1993;117: 46-53.
23. Lilienfeld DE, Chan E, Ehland J, et al. Rising mortality from motor neuron disease in the USA, 1962-1984. Lancet 1988;i:710-3.
24. Riggs JE. Longitudinal Gompertzian analysis of amyotrophic lateral sclerosis mortality in the USA, 1977-1986: evidence for an inherently susceptible population subset. Mech Ageing Dev 1990;55:207-20.
25. Roman GC, Zhang Z-X, Ellenberg JH. The neuroepidemiology of Parkinson's disease. In: Ellenberg JH, Koller WC, Langston JW, eds. Etiology of Parkinson's disease. New York: Dekker, 1995:203-43.
26. Chiò A, Meineri P, Tribolo A, Schiffer D. Risk factors in motor neuron disease: a case-control study. Neuroepidemiology 1991;10:174-84.
27. Granieri E, Rosati G, Paolino E, Tola R, Aiello I, Granieri S. The risk of amyotrophic lateral sclerosis among laborers in Sardinia, Italy: a case-control study [abstract]. J Neurol 1985;232(suppl):15.30.
28. Holloway S, Emery AEH. The epidemiology of motor neuron disease in Scotland. Muscle Nerve 1982;5:131-3.
29. Giagheddu M, Puggioni G, Masala C, et al. Epidemiologic study of amyotrophic lateral sclerosis in Sardinia, Italy. Acta Neurol Scand 1983;68:394-404.
30. Bharucha NE, Schoenberg BS, Raven RH, Pickle LW, Byar DP, Mason TJ. Geographic distribution of motor neuron disease and correlation with possible etiologic factors. Neurology 1983;33:911-5.
31. Granieri E, Carreras M, Tola R, Paolino E, Troill G, Eleofra R, Serra G. Motor neuron disease in the Province of Ferrara, Italy, 1964-1982. Neurology 1988;38:1604-8.
32. Angelini C, Armani M, Bresolin N. Incidence and risk factors of motor neuron disease in the Venice and Padua districts of Italy, 1972-1979. Neuroepidemiology 1983;2: 236-40.
33. Hochberg FH, Bryan JA, Whelan MA. Clustering of amyotrophic lateral sclerosis. Lancet 1974;i:34.
34. Melmed C, Krieger C. A cluster of amyotrophic lateral sclerosis. Arch Neurol 1982;39:595-6.
35. Sanders M. Clustering of amyotrophic lateral sclerosis. JAMA 1980;244:435.
36. Hyser CL, Kissel JT, Mendell JR. Three cases of amyotrophic lateral sclerosis in a common occupational environment. J Neurol 1987;234:443-4.
37. Proctor SP, Feldman RG, Wolf PA, Brent B, Wartenberg D. A perceived cluster of amyotrophic lateral sclerosis in a Massachusetts community. Neuroepidemiology 1992;1: 277-81.
38. Armon C, Daube JR, O'Brien PC, Kurland LT, Mulder DW. When is an apparent excess of neurologic cases epidemiologically significant? Neurology 1991;41:1713-8.
39. Gunnarsson L-G, Lindberg G, Söderfeldt B, Axelson O. The mortality of motor neuron disease in Sweden 1961-85. Arch Neurol 1990;47:42-6.
40. Gunnarsson L-G, Lygner P-E, Veiga-Cabo J, De-Pedro-Cuesta J. An epidemic-like cluster of motor neuron disease in a Swedish county during the period 1973-1984. Neuroepidemiology 1995;.
41. Gunnarsson L-G, Bodin G, Söderfeldt B, Axelson O. A case-control study of motor neuron disease: its relation to heritability, and occupational exposures, particularly to solvents. Br J Ind Med 1992;49:791-8.
42. Gunnarsson L-G. Motor neuron disease and exposure to chemicals - aetiological suggestions from a case-control study. J Neurol Sci 1994;124(suppl):62-3.
43. Kurtzke JF. Risk factors in amyotrophic lateral sclerosis. Adv Neurol 1991;56:245-70.
44. Kurland LT, Radhakrishnan K, Smith GE, Armon G, Nemetz PN. Mechanical trauma as a risk factor in classic amyotrophic lateral sclerosis: lack of epidemiologic evidence. J Neurol Sci 1992;113:133-43.
45. Appel SH, Smith RG, Engelhardt JT, Stefani E. Evidence for autoimmunity in amyotrophic lateral sclerosis. J Neurol Sci 1994;124(suppl):14-9.
46. Rowland LP. Amyotrophic lateral sclerosis with paraproteins and autoantibodies. Adv Neurol 1995;68:93-105.
47. Swingler RJ, Fraser H, Harlow CP. Motor neuron disease and polio in Scotland. J Neurol Neurosurg Psychiatry 1992;55:1116-20.
48. Okumura H, Kurland LT, Waring SC. Amyotrophic lateral sclerosis and polio: is there an association? Ann NY Acad Sci 1995;753:245-56.
49. Román GC, Vernant J-C, Osame M. HTLV-I-associated motor neuron disease. Handbook Clin Neurol 1991;59: 447-57.
50. Ferrante P, Westarp ME, Mancuso R, et al. HTLV tax-rex DNA and antibodies in idiopathic amyotrophic lateral sclerosis. J Neurol Sci 1995;129(suppl):140-4.
51. Westarp ME, Ferrante P, Perron H, Bartmann P, Kornhuber HH. Sporadic ALS/MND: a global neurodegeneration with retroviral involvement. J Neurol Sci 1995; 129(suppl):145-7.
52. Wiedau-Pazos M, Goto JJ, Rabizadeh S, et al. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science 1996;271:515-8.
53. Plaitikis A, Caroscio JT. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 1987;22: 575-9.
54. Plaitikis A, Mandeli J, Fesdjian C, Sivak MA. Dysregulation of glutamate metabolism in ALS: correlation with gender and disease type. Neurology 1991;41:392-3.
55. Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18-25.
56. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992;326:1464-8.
57. Shaw PJ. Excitotoxicity and motor neurone disease: a review of the evidence. J Neurol Sci 1994;24(suppl):6-13.
58. Bensimon G, Lacomblez L, Meininger V, ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330: 585-91.
59. Gourie-Devi M, ed. Motor neuron disease: global clinical patterns and international research. New Delhi: Oxford and IBH Publishing Co, 1988.
60. Hentati A, Bejaoui K, Pericak-Vance MA, et al. Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-q35. ACI Nature Genetics 1994;7:425-8.
61. Kurland LT, Mulder DW. Epidemiologic investigations of amyotrophic lateral sclerosis. I. Preliminary report on geographic distribution, with special reference to the Mariana Islands, including clinical and pathologic observations. Neurology 1954;4:355-78.
62. Reed DM, Brody JA. Amyotrophic lateral sclerosis and parkinsonism-dementia on Guam, 1945-1972. I: Descriptive epidemiology. Am J Epidemiol 1975;101: 287-301.
63. Garruto RM, Yanagihara R, Gajdusek DC. Disappearance of high-incidence amyotrophic lateral sclerosis and parkinsonism-dementia on Guam. Neurology 1985;35:193-8.
64. Reed D, Labarthe D, Chen KM, Stallones R. A cohort study of amyotrophic lateral sclerosis and parkinsonism-dementia on Guam and Rota. Am J Epidemiol 1987;125: 92-100.
65. Araki S, Iwasashi Y, Kuroiwa Y. Epidemiological study of amyotrophic lateral sclerosis and allied disorders in the Kii Peninsula (Japan). J Neurol Sci 1967;4:279-82.
66. Gajdusek DC, Salazar AM. Amyotrophic lateral sclerosis and parkinsonian syndromes in high incidence among the Auyu and Jakai people of West New Guinea. Neurology 1982;32:107-26.
67. Zhang ZX, Anderson DW, Mantel N, Román GC. Motor neuron disease on Guam. Temporal occurrence, 1941-85. Acta Neurol Scand 1995;92:299-307.
68. Zhang ZX, Anderson DW, Mantel N, Roman GC. Motor neuron disease on Guam: geographic and familial occurrence, 1956-85. Acta Neurol Scand 1996;94:51-9.
69. Kurland LT, Mulder DW. Epidemiologic investigations of amyotrophic lateral sclerosis. II. Familial aggregations indicative of dominant inheritance, part 1. Neurology 1955;5:182-96.
70. Reed DM, Torres JM, Brody JA. Amyotrophic lateral sclerosis and parkinsonism-dementia on Guam, 1945-1972. II: Familial and genetic studies. Am J Epidemiol 1975; 101:302-10.
71. Spencer PS, Nunn PB, Hugon J, et al. Guam amyotrophic lateral sclerosis-Parkinsonism-dementia linked to a plant excitant neurotoxin. Science 1987;237:517-22.
72. Garruto RM. Neurotoxicity of trace and essential elements: factors provoking the high incidence of motor neuron disease, Parkinsonism and dementia in the Western Pacific. In: Gouri-Devi M, ed: Motor neurone disease: global clinical patterns and international research. New Delhi: Oxford and IBH Publishing Co, 1987:73-82.
73. Steele JC, Guzman T. Observations about amyotrophic lateral sclerosis and the Parkinsonism-dementia complex of Guam with regard to epidemiology and etiology. Can J Neurol Sci 1987;14(suppl):358-62.
74. Kisby GE, Ellison M, Spencer PS. Content of the neurotoxins cycasin (methylazoxymethanol β-D-glucoside) and BMAA (β-N-methylamino-L-alanine) in cycad flour prepared by Guam Chamorros. Neurology 1992;42:1336-40.
75. Garruto RM, Yanagihara R, Gajdusek DC, Arion DM. Concentrations of heavy metals and essential minerals in garden soil and drinking water in the western Pacific. In: Chen KM, Chase Y, eds. Amyotrophic lateral sclerosis in Asia and Oceania. Taiwan, Republic of China: National Taiwan University, 1984:265-330.
76. Kurland LT, Molgaard CA. Guamanian ALS: hereditary or acquired? In: Rowland LP, ed. Human motor neuron diseases. New York: Raven Press, 1982:165-71.
77. Kisby GE, Ross SM, Spencer PS, et al. Cycasin and BMAA: Candidate neurotoxins for western Pacific amyotrophic lateral sclerosis/parkinsonism-dementia complex. Neurodegeneration 1992;1:73-82.
78. Spencer PS, Kisby GE, Ross SM, Roy DN, Hugon J, Ludolph AC, Nunn PB. Guam ALS-PDC: possible causes. Science 1993;262:825-6.
79. Perl DP, Gajdusek DC, Garruto RM, Yanagihara RT, Gibbs CJ. Intraneuronal aluminum accumulation in amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam. Science 1982;217:1053-5.
80. Garruto RM, Shankar SK, Yanagihara R, Salazar AM, Amyx HL, Gajdusek DC. Low calcium, high aluminum diet-induced motor neuron pathology in cynomolgus monkeys. Acta Neuropathol 1989;78:210-9.
81. Strong MJ, Garruto RM. Chronic aluminum-induced motor neuron degeneration: clinical, neuropathological and molecular biological aspects. Can J Neurol Sci 1991; 18:431.
82. Jellinger K, Kienzl E. Iron deposits in brain disorders. In: Riederer P, Youdim MBH, eds. Iron in central nervous system disorders. New York: Springer Verlag, 1993:19-36.
83. Koeppen AH, ed. Normal and pathological brain iron. J Neurol Sci 1995;134(suppl):1-114.
84. Levuegle B, Spik G, Perl DP, Bouras C, Fillit HM, Hof PR. The iron-binding protein lactotransferrin is present in pathological lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res 1994;650:20-31.
85. Brown RH. Superoxide dismutase and familial amyotrophic lateral sclerosis: new insights into mechanisms and treatments. Ann Neurol 1996;39:145-6.
86. Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, Hall ED. Benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-57.
87. Heafield MT, Fearn S, Stevenson GB, Waring RH, Williams AC, Sturman SG. Plasma cysteine and sulphate levels in patients with motor neurone, Parkinson's and Alzheimer's disease. Neurosci Lett 1990;110:216-20.